Cargando…
Computer-assisted drug discovery (CADD) of an anti-cancer derivative of the theobromine alkaloid inhibiting VEGFR-2
VEGFR-2 is a significant target in cancer treatment, inhibiting angiogenesis and impeding tumor growth. Utilizing the essential pharmacophoric structural properties, a new semi-synthetic theobromine analogue (T-1-MBHEPA) was designed as VEGFR-2 inhibitor. Firstly, T-1-MBHEPA's stability and rea...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10663924/ https://www.ncbi.nlm.nih.gov/pubmed/38028225 http://dx.doi.org/10.1016/j.jsps.2023.101852 |
_version_ | 1785138507328520192 |
---|---|
author | Eissa, Ibrahim H. Yousef, Reda G. Asmaey, Mostafa A. Elkady, Hazem Husein, Dalal Z. Alsfouk, Aisha A. Ibrahim, Ibrahim M. Elkady, Mohamed A. Elkaeed, Eslam B. Metwaly, Ahmed M. |
author_facet | Eissa, Ibrahim H. Yousef, Reda G. Asmaey, Mostafa A. Elkady, Hazem Husein, Dalal Z. Alsfouk, Aisha A. Ibrahim, Ibrahim M. Elkady, Mohamed A. Elkaeed, Eslam B. Metwaly, Ahmed M. |
author_sort | Eissa, Ibrahim H. |
collection | PubMed |
description | VEGFR-2 is a significant target in cancer treatment, inhibiting angiogenesis and impeding tumor growth. Utilizing the essential pharmacophoric structural properties, a new semi-synthetic theobromine analogue (T-1-MBHEPA) was designed as VEGFR-2 inhibitor. Firstly, T-1-MBHEPA's stability and reactivity were indicated through several DFT computations. Additionally, molecular docking, MD simulations, MM-GPSA, PLIP, and essential dynamics (ED) experiments suggested T-1-MBHEPA's strong binding capabilities to VEGFR-2. Its computational ADMET profiles were also studied before the semi-synthesis and indicated a good degree of drug-likeness. T-1-MBHEPA was then semi-synthesized to evaluate the design and the in silico findings. It was found that, T-1-MBHEPA inhibited VEGFR-2 with an IC(50) value of 0.121 ± 0.051 µM, as compared to sorafenib which had an IC(50) value of 0.056 µM. Similarly, T-1-MBHEPA inhibited the proliferation of HepG2 and MCF7 cell lines with IC(50) values of 4.61 and 4.85 µg/mL respectively - comparing sorafenib's IC(50) values which were 2.24 µg/mL and 3.17 µg/mL respectively. Interestingly, T-1-MBHEPA revealed a noteworthy IC(50) value of 80.0 µM against the normal cell lines exhibiting exceptionally high selectivity indexes (SI) of 17.4 and 16. 5 against the examined cell lines, respectively. T-1-MBHEPA increased the percentage of apoptotic MCF7 cells in early and late stages, respectively, from 0.71 % to 7.22 % and from 0.13 % to 2.72 %, while the necrosis percentage was increased to 11.41 %, in comparison to 2.22 % in control cells. Furthermore, T-1-MBHEPA reduced the production of pro-inflammatory cytokines TNF-α and IL-2 in the treated MCF7 cells by 33 % and 58 %, respectively indicating an additional anti-angiogenic mechanism. Also, T-1-MBHEPA decreased significantly the potentialities of MCF7 cells to heal and migrate from 65.9 % to 7.4 %. Finally, T-1-MBHEPA’s oral treatment didn’t show toxicity on the liver function (ALT and AST) and the kidney function (creatinine and urea) levels of mice. |
format | Online Article Text |
id | pubmed-10663924 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-106639242023-11-02 Computer-assisted drug discovery (CADD) of an anti-cancer derivative of the theobromine alkaloid inhibiting VEGFR-2 Eissa, Ibrahim H. Yousef, Reda G. Asmaey, Mostafa A. Elkady, Hazem Husein, Dalal Z. Alsfouk, Aisha A. Ibrahim, Ibrahim M. Elkady, Mohamed A. Elkaeed, Eslam B. Metwaly, Ahmed M. Saudi Pharm J Article VEGFR-2 is a significant target in cancer treatment, inhibiting angiogenesis and impeding tumor growth. Utilizing the essential pharmacophoric structural properties, a new semi-synthetic theobromine analogue (T-1-MBHEPA) was designed as VEGFR-2 inhibitor. Firstly, T-1-MBHEPA's stability and reactivity were indicated through several DFT computations. Additionally, molecular docking, MD simulations, MM-GPSA, PLIP, and essential dynamics (ED) experiments suggested T-1-MBHEPA's strong binding capabilities to VEGFR-2. Its computational ADMET profiles were also studied before the semi-synthesis and indicated a good degree of drug-likeness. T-1-MBHEPA was then semi-synthesized to evaluate the design and the in silico findings. It was found that, T-1-MBHEPA inhibited VEGFR-2 with an IC(50) value of 0.121 ± 0.051 µM, as compared to sorafenib which had an IC(50) value of 0.056 µM. Similarly, T-1-MBHEPA inhibited the proliferation of HepG2 and MCF7 cell lines with IC(50) values of 4.61 and 4.85 µg/mL respectively - comparing sorafenib's IC(50) values which were 2.24 µg/mL and 3.17 µg/mL respectively. Interestingly, T-1-MBHEPA revealed a noteworthy IC(50) value of 80.0 µM against the normal cell lines exhibiting exceptionally high selectivity indexes (SI) of 17.4 and 16. 5 against the examined cell lines, respectively. T-1-MBHEPA increased the percentage of apoptotic MCF7 cells in early and late stages, respectively, from 0.71 % to 7.22 % and from 0.13 % to 2.72 %, while the necrosis percentage was increased to 11.41 %, in comparison to 2.22 % in control cells. Furthermore, T-1-MBHEPA reduced the production of pro-inflammatory cytokines TNF-α and IL-2 in the treated MCF7 cells by 33 % and 58 %, respectively indicating an additional anti-angiogenic mechanism. Also, T-1-MBHEPA decreased significantly the potentialities of MCF7 cells to heal and migrate from 65.9 % to 7.4 %. Finally, T-1-MBHEPA’s oral treatment didn’t show toxicity on the liver function (ALT and AST) and the kidney function (creatinine and urea) levels of mice. Elsevier 2023-12 2023-11-02 /pmc/articles/PMC10663924/ /pubmed/38028225 http://dx.doi.org/10.1016/j.jsps.2023.101852 Text en © 2023 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Article Eissa, Ibrahim H. Yousef, Reda G. Asmaey, Mostafa A. Elkady, Hazem Husein, Dalal Z. Alsfouk, Aisha A. Ibrahim, Ibrahim M. Elkady, Mohamed A. Elkaeed, Eslam B. Metwaly, Ahmed M. Computer-assisted drug discovery (CADD) of an anti-cancer derivative of the theobromine alkaloid inhibiting VEGFR-2 |
title | Computer-assisted drug discovery (CADD) of an anti-cancer derivative of the theobromine alkaloid inhibiting VEGFR-2 |
title_full | Computer-assisted drug discovery (CADD) of an anti-cancer derivative of the theobromine alkaloid inhibiting VEGFR-2 |
title_fullStr | Computer-assisted drug discovery (CADD) of an anti-cancer derivative of the theobromine alkaloid inhibiting VEGFR-2 |
title_full_unstemmed | Computer-assisted drug discovery (CADD) of an anti-cancer derivative of the theobromine alkaloid inhibiting VEGFR-2 |
title_short | Computer-assisted drug discovery (CADD) of an anti-cancer derivative of the theobromine alkaloid inhibiting VEGFR-2 |
title_sort | computer-assisted drug discovery (cadd) of an anti-cancer derivative of the theobromine alkaloid inhibiting vegfr-2 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10663924/ https://www.ncbi.nlm.nih.gov/pubmed/38028225 http://dx.doi.org/10.1016/j.jsps.2023.101852 |
work_keys_str_mv | AT eissaibrahimh computerassisteddrugdiscoverycaddofananticancerderivativeofthetheobrominealkaloidinhibitingvegfr2 AT yousefredag computerassisteddrugdiscoverycaddofananticancerderivativeofthetheobrominealkaloidinhibitingvegfr2 AT asmaeymostafaa computerassisteddrugdiscoverycaddofananticancerderivativeofthetheobrominealkaloidinhibitingvegfr2 AT elkadyhazem computerassisteddrugdiscoverycaddofananticancerderivativeofthetheobrominealkaloidinhibitingvegfr2 AT huseindalalz computerassisteddrugdiscoverycaddofananticancerderivativeofthetheobrominealkaloidinhibitingvegfr2 AT alsfoukaishaa computerassisteddrugdiscoverycaddofananticancerderivativeofthetheobrominealkaloidinhibitingvegfr2 AT ibrahimibrahimm computerassisteddrugdiscoverycaddofananticancerderivativeofthetheobrominealkaloidinhibitingvegfr2 AT elkadymohameda computerassisteddrugdiscoverycaddofananticancerderivativeofthetheobrominealkaloidinhibitingvegfr2 AT elkaeedeslamb computerassisteddrugdiscoverycaddofananticancerderivativeofthetheobrominealkaloidinhibitingvegfr2 AT metwalyahmedm computerassisteddrugdiscoverycaddofananticancerderivativeofthetheobrominealkaloidinhibitingvegfr2 |